Technical Analysis for BGNE - BeiGene, Ltd.

Grade Last Price % Change Price Change
grade C 133.27 5.34% 6.75
BGNE closed up 5.34 percent on Thursday, October 17, 2019, on 61 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical BGNE trend table...

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Stochastic Reached Overbought Strength 0.00%
Multiple of Ten Bullish Other 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 5.34%

Older signals for BGNE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Biopharmaceutical Cancers Monoclonal Antibodies Humanized Antibody Oncogenes Lymphomas Ras Subfamily Braf Kras
Is BGNE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 164.99
52 Week Low 105.19
Average Volume 328,800
200-Day Moving Average 130.8508
50-Day Moving Average 132.019
20-Day Moving Average 124.262
10-Day Moving Average 121.771
Average True Range 4.8153
ADX 18.44
+DI 30.4735
-DI 20.1223
Chandelier Exit (Long, 3 ATRs ) 123.4141
Chandelier Exit (Short, 3 ATRs ) 128.9659
Upper Bollinger Band 136.5903
Lower Bollinger Band 111.9337
Percent B (%b) 0.87
BandWidth 19.84243
MACD Line -1.6996
MACD Signal Line -3.198
MACD Histogram 1.4984
Fundamentals Value
Market Cap 5.31 Billion
Num Shares 39.8 Million
EPS -4.97
Price-to-Earnings (P/E) Ratio -26.81
Price-to-Sales 0.00
Price-to-Book 12.46
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 142.29
Resistance 3 (R3) 141.39 137.48 140.78
Resistance 2 (R2) 137.48 135.19 137.93 140.28
Resistance 1 (R1) 135.38 133.77 136.43 136.28 139.78
Pivot Point 131.47 131.47 132.00 131.92 131.47
Support 1 (S1) 129.37 129.18 130.42 130.27 126.76
Support 2 (S2) 125.46 127.76 125.91 126.26
Support 3 (S3) 123.36 125.46 125.76
Support 4 (S4) 124.26